D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. It is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; K-321 to treat fuch endothelial corneal dystrophy which is in Phase III clinical trials; and H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension. The company was founded in 1999 and is headquartered in Nagoya, Japan.
Metrics to compare | 4576 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4576PeersSector | |
---|---|---|---|---|
P/E Ratio | −4.3x | −6.1x | −0.6x | |
PEG Ratio | −0.20 | 0.01 | 0.00 | |
Price/Book | 5.3x | 4.2x | 2.6x | |
Price / LTM Sales | 11.2x | 43.5x | 3.3x | |
Upside (Analyst Target) | - | 84.4% | 38.7% | |
Fair Value Upside | Unlock | 20.7% | 5.1% | Unlock |